New York esophageal squamous cell carcinoma 1 (NY-ESO-1, CTAG1B) is a cancer-testis antigen and currently a focus of several targeted immunotherapeutic strategies. We performed a large-scale immunohistochemical expression study of NY-ESO-1 using tissue microarrays of mesenchymal tumors from three institutions in an international collaboration. A total of 1132 intermediate and malignant and 175 benign mesenchymal lesions were enrolled in this study. Immunohistochemical staining was performed on tissue microarrays using a monoclonal antibody for NY-ESO-1. Among mesenchymal tumors, myxoid liposarcomas showed the highest positivity for NY-ESO-1 (88%), followed by synovial sarcomas (49%), myxofibrosarcomas (35%), and conventional chondrosarcomas (28%). Positivity of NY-ESO-1 in the remaining mesenchymal tumors was consistently low, and no immunoreactivity was observed in benign mesenchymal lesions. On the basis of these findings, nearly 90% of myxoid liposarcomas, as well as a significant proportion of synovial sarcomas, myxofibrosarcomas, and conventional chondrosarcomas are good candidates for immunotherapy targeting NY-ESO-1. Modern Pathology (2015) 28, 587-595; doi:10.1038/modpathol.2014.155; published online 21 November 2014
New York esophageal squamous cell carcinoma 1 (NY-ESO-1), encoded by the CTAG1B gene, is a cancer-testis antigen that was identified in 1997 from the serum of a patient with esophageal squamous cell carcinoma. 1 Cancer-testis antigens such as NY-ESO-1 have attracted increasing attention as immunotherapeutic targets because, among normal tissues, they are expressed only in adult testis germ cells and are atypically re-expressed in many malignancies. 2, 3 NY-ESO-1 is of particular interest to researchers and clinicians because it is highly immunogenic and is expressed in a variety of carcinomas, melanomas, and sarcomas. 4 A recent clinical trial of adoptive immunotherapy, using genetically modified T cells directed against NY-ESO-1, demonstrated objective clinical responses in a number of metastatic synovial sarcoma and melanoma patients with NY-ESO-1-positive tumors. 5 The results of that clinical trial highlight the potential effectiveness of immunotherapy against tumors expressing NY-ESO-1, and several clinical trials (using antigen sensitization, adoptive T-cell transfer, and dendritic cell vaccine strategies) are currently underway.
Mesenchymal tumors arising from bone or soft tissues comprise many histologic subtypes, which even when taken together occur at a much lower rate than the more common carcinomas, creating a practical barrier to developing new drug therapies. However, the well-defined biology of many sarcomas suggests they may be particularly susceptible to appropriate targeted strategies. Recent studies have reported NY-ESO-1 expression in an especially large proportion of myxoid liposarcomas and synovial sarcomas. 2, [6] [7] [8] [9] These studies also revealed the absence of NY-ESO-1 expression in their histologic mimics such as myxoma, myxofibrosarcoma, extraskeletal myxoid chondrosarcoma, and lowgrade fibromyxoid sarcoma, and concluded that immunohistochemical staining of NY-ESO-1 is useful not only for candidate selection in immunotherapy, but also for histologic differential diagnosis. A limitation of these previous studies is that the sample sizes were too small to be conclusive and lacked independent external validation.
The goals of this study are to validate published reports of NY-ESO-1 expression in myxoid liposarcoma and synovial sarcoma patients on a larger sample set, and to investigate NY-ESO-1 expression in other mesenchymal tumors not represented in previous studies. To do so, we undertook a multiinstitutional NY-ESO-1 expression survey on tissue microarrays encompassing a wide variety of malignant, intermediate, and benign bone and soft tissue tumors, seeking to determine whether NY-ESO-1 is indeed useful in the differential diagnosis among mesenchymal tumors and to identify subtypes that are most likely to benefit from NY-ESO-1 immunotherapy.
Materials and methods

Tumor Samples and Tissue Microarrays
In this study, formalin-fixed paraffin-embedded tissue microarrays from three institutions, the University of British Columbia (UBC), the MD Anderson Cancer Center (MDACC), and the Leiden University Medical Center (LUMC), with a diverse selection of benign, intermediate, and malignant mesenchymal tumors were used. Each tissue microarray contains duplicate, triplicate, or quadruplicate 0.6 mm (UBC, LUMC), 1.5 mm (LUMC), or 2.0 mm (MDACC, LUMC) cores derived from representative viable diagnostic areas identified by a specialized bone and soft tissue tumor pathologist (TON, AJL, JVMGB). Tissue microarrays from UBC included in this study are TMA 01-003, 10 TMA 03-008, 11 TMA 06-007, 12 TMA 06-001B, 13 TMAs 08-019, 09-006, 10-009, 14 TMAs 12-004, 12-005, 12-006, 12-010, 15 and TMA MPNST. 16 From MDACC, myxoid liposarcoma tissue microarrays contained untreated tumors and tumors pre-treated with chemotherapy, radiation, or a combination of both. 17, 18 From the LUMC, tissue microarrays were selected containing chondrosarcomas, 19, 20 osteosarcomas, 21 myxoid liposarcomas, and a variety of benign and malignant soft tissue tumors. 22, 23 Immunohistochemistry Immunohistochemical staining was performed with an autostainer for tissue microarrays of the UBC and MDACC following protocols as described previously. 24 Briefly, antigen retrieval was performed using the Standard Cell Conditioning 1 (CC1) protocol (Ventana, Tucson, AZ, USA). Sections were incubated with mouse anti-NY-ESO-1 monoclonal antibody (clone E978, Invitrogen, Carlsbad, CA, USA) at 1:25 dilution for 2 h at room temperature, and then with UltraMap HRP-conjugated anti-mouse IgG secondary antibody for 16 min. The ChromoMap DAB Kit (Ventana) provided the visualization chromogen. Slides were then counterstained with hematoxylin and mounted. Immunohistochemical staining of the tissue microarrays of the LUMC was performed manually; 4 mm sections were transferred to adhesive-coated slides (Leica Biosystems, Rijswijk, The Netherlands) and dried overnight at 37 1C. Next slides were deparaffinized in xylene, rehydrated and incubated in 0.3% methanol/H 2 O 2 at room temperature for 20 min to block the endogenous peroxidase activity. Antigen retrieval was performed by 10 min microwave treatment in tris/EDTA-solution (pH ¼ 9.0), followed by the addition of the primary NY-ESO-1 / CTAG1B antibody (1:100, clone E978, Invitrogen) and overnight incubation in a moist chamber at room temperature. Next, slides were incubated with PowerVision Poly-HRP (Leica), visualized with DAB þ Substrate Chromogen System (DAKO, Heverlee, Belgium) and counterstained with hematoxylin. All wash steps were carried out in PBS.
In both protocols, the staining was preceded by a titration series on normal testis, and during the actual staining, testis was included as a positive control, and as the tissue present in the negative control reaction (without the addition of the primary antibody).
Digital Images
Digital images of immunostained and H&E-stained tissue microarrays of UBC were acquired using a BLISS imager (Bacus Laboratories, Lombard, IL, USA). A relational database was constructed that correlates scoring and identification information with images of each core. This information is publicly accessible at http://www.gpecimage.ubc.ca (username: nyeso1; password: nyeso1).
Evaluation of Immunohistochemistry
The tissue microarray slides were evaluated under a light microscope or on the scanned images by two to five independent observers (ME, MAG, TON, JVMGB, AJL), including three experienced bone and soft tissue tumor subspecialty pathologists (TON, JVMGB, AJL). NY-ESO-1 immunopositivity was scored in a semiquantitative manner for the intensity (0 ¼ negative, 1 ¼ weak positive, 2 ¼ moderate positive, 3 ¼ strong positive) and the percentage of positive tumor cells (0
Each core on the tissue microarrays was scored separately and the
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average score from cores of the same tumor were calculated. Tumor samples with more than 50% of positive tumor cells and a staining intensity of moderate or strong (2 or 3) were defined as 'positive'. This cutoff value was chosen to be consistent with criteria used in an ongoing clinical trial of NY-ESO-1 immunotherapy. 5 In addition, cross comparison of manual and autostaining revealed the manual method generated a weak background stain not seen with the automated platform. However, the scoring system, which considered weak (intensity 1) staining as negative meant that the cases defined as 'positive' were consistently categorized and equally discernible with both staining methods. Comparison of TMA with the whole section was performed on a comparison set of 11 cases, and the staining results were found to be concordant.
Statistical Analysis
A chi-square test was used to assess the differences between histological subtypes; statistical significance was defined as Po0.05. Data analysis was performed with JMP software (version 9.0.2, JMP Software, Cary, NC, USA).
Results
In total, specimens from 1132 malignant and intermediate bone and soft tissue tumors, 175 benign bone and soft tissue tumors, 50 non-mesenchymal tumors, 6 non-tumorous lesions, and 8 samples of normal fat were available for evaluation (Tables 1-3 ). There were 38 subtypes of malignant and intermediate tumors and 21 different benign mesenchymal lesions in this cohort. The subtypes with more than 50 samples available included myxoid liposarcoma (n ¼ 201 in total; 158 untreated cases, and 43 tumors that received treatment prior to resection), gastrointestinal stromal tumor (n ¼ 146), conventional chondrosarcoma (n ¼ 142), malignant peripheral nerve sheath tumor (n ¼ 82), osteosarcoma (n ¼ 80), synovial sarcoma (n ¼ 69), endometrial stromal sarcoma (n ¼ 58), and leiomyosarcoma (n ¼ 55).
Among a wide variety of mesenchymal tumors, myxoid liposarcomas that had not received neoadjuvant treatment prior to resection showed the highest positivity for NY-ESO-1 (CTAG1B): 88.0% (139/158). The high number of positive cases was observed both in the autostained cohort cases from UBC and MDACC (85.9%; 110/128) and in the manually stained cohort cases from LUMC (96.7%; 29/30). Even among myxoid liposarcomas that received chemotherapy or radiation prior to resection, NY-ESO-1 expression was still detectable in 41.9% (18/43) of cases, although this was significantly lower (Po0.0001) compared with the cases without preoperative treatment. Expression was seen both in myxoid as well as round cell areas. In an additional 37.2% (16/43) of these neoadjuvantly treated tumors, weak staining in a small subset of the tumor cells was present; the remaining 20.9% (9/43) did not reveal any residual immunoreactivity. In comparison, the other liposarcomas-including well-differentiated (4.8% positivity; 1/21) and dedifferentiated (14.3%; 1/7) subtypes-showed NY-ESO-1 expression in only a minor subset of the cases; none of the tested pleomorphic liposarcomas revealed NY-ESO-1 expression (0%; 0/11). NY-ESO-1 positivity in myxoid liposarcomas was significantly higher than in the other liposarcomas (Po0.0001) or in the other malignant and intermediate bone and soft tissue tumors (Po0.0001).
NY-ESO-1 expression was observed in almost half (49.3%; 34/69) of the synovial sarcomas. In addition, positivity was found in conventional chondrosarcoma (28.2%; 40/142) and dedifferentiated chondrosarcoma (10.0%; 3/30). In the conventional chondrosarcomas, there was no correlation of NY-ESO-1 expression and histological grade. Two of the positive dedifferentiated chondrosarcomas revealed NY-ESO-1 expression only in the dedifferentiated component and the third positive case showed immunoreactivity in the well-differentiated component.
Other sarcomas with a substantial percentage of positive tumors include myxofibrosarcoma (35.3%; 6/17), leiomyosarcoma (14.5%; 8/55), dermatofibrosarcoma protuberans (11.1%; 2/18-including one of nine cases with fibrosarcomatous change), and undifferentiated pleomorphic sarcoma (11.1%; 3/27). Pleomorphic rhabdomyosarcoma (33.3%; 1/3) and fibrosarcoma (12.5%; 1/8) also presented positivity in a minority of the cases, although the sample size was small. The 175 benign bone and soft tissue tumors, the 6 non-tumorous lesions, and the 8 normal fat samples were all negative for NY-ESO-1. In the group of the non-mesenchymal tumors, 10% (1/10) of the desmoplastic melanomas and none of the other melanomas showed NY-ESO-1 positivity.
Positive controls of formalin-fixed, paraffinembedded testis sections revealed strong NY-ESO-1 expression among spermatogonia and spermatocytes in the seminiferous tubules. No immunoreactivity was observed in any of the negative controls. Representative results of a selection of malignant bone and soft tissue tumors are shown in Figures 1-3 .
Discussion
To the best of our knowledge, this is the largest-scale NY-ESO-1 (CTAG1B) expression study in bone and soft tissue tumors, including over 1300 specimens representing 38 malignant and borderline and 21 benign histologic subtypes. Of special note is the inclusion in our study of 201 myxoid liposarcomas and 69 synovial sarcomas-two sarcoma subtypes 
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that have been considered to be potentially good candidates for NY-ESO-1 immunotherapy. We employed a cutoff value for immunohistochemical positivity by reference to the eligibility of an antecedent clinical trial of immunotherapy targeting NY-ESO-1. 5 Myxoid liposarcoma represents 20-30% of all liposarcomas, mostly occurs in young adults, and is characterized by a translocation t(12;16)(q13;p11) or, in a few percent of the cases, a t(12;22)(q13;q12), leading to the chimeric fusion product FUS-DDIT3 or EWSR1-DDIT3, respectively. 25, 26 According to the literature, one-third of myxoid liposarcoma patients develop distant metastases, 18, 27, 28 so effective systemic therapy is needed to improve the prognosis of many patients. Previous studies reported NY-ESO-1 expression in 95-100% of myxoid liposarcomas; these results were based on sample sizes ranging from 25 to 38 cases. 6, 9 Our larger study revealed that 139 out of the 158 (88.0%) untreated myxoid liposarcomas were positive for NY-ESO-1, and concurs with the rate of positivity reported in the previous studies. The slightly lower rate of positivity might be attributable to the fact that some tumors only display a focal NY-ESO-1 positivity, which might be missed because of the use of tissue microarrays. Hemminger et al 9 reported that other liposarcoma subtypes, lipomas, and other myxoid mesenchymal tumors were negative for NY-ESO-1, suggesting that NY-ESO-1 could be a and therefore its expression helps to discriminate myxoid liposarcoma from tumors in the differential diagnosis. Interestingly, chemotherapy-or radiation-pretreated myxoid liposarcomas showed a lower positivity for NY-ESO-1. The biological mechanism behind the decreasing NY-ESO-1 positivity after the preoperative treatment is unknown; however, some of these samples at histological examination showed a low tumor cell density with hyalinization, reactive matrix, and weak NY-ESO-1 staining below the intensity required to label the tumor as positive. NY-ESO-1 expression is still more frequent even in treated myxoid liposarcomas than in other sarcomas; therefore, NY-ESO-1-targeted immunotherapy combined with established therapies remains an attractive potential strategy. This observed reduction in NY-ESO-1 positivity in post-treatment myxoid liposarcoma was not seen in a set of eight additional synovial sarcoma specimens, in which all retained strongly positive expression following neoadjuvant treatment (radiation þ / À chemotherapy) (Data not shown).
Synovial sarcoma is a translocation-associated sarcoma characterized by the fusion gene, SS18-SSX1, -SSX2, or -SSX4. 29 More than half of the patients are teenagers and young adults. The development of novel systemic therapies is important because metastasis of synovial sarcoma is common (overall 5-year metastasis-free survival rate 51.1%). 30 Jungbluth et al 31 49.3% positivity across 69 cases of synovial sarcoma, somewhat lower than that of the previous papers, possibly because of the decreased sensitivity using the tissue microarray platform. Considering the combined results from our and previous studies, approximately half to three quarters of synovial sarcomas show NY-ESO-1 expression.
In a recent clinical trial using genetically engineered autologous T lymphocytes reactive with NY-ESO-1, four of the six advanced synovial sarcoma patients who received immunotherapy showed documented partial responses; 5 worth noting is that this response lasted at least 18 months in one patient. This result has encouraged the development of NY-ESO-1-targeted immunotherapy not only for synovial sarcomas, but also for other NY-ESO-1 expressing sarcomas including myxoid liposarcomas. Public information on clinicaltrials.gov lists at least 14 clinical trials employing vaccine, autologous T-cell, or dendritic cell transduction immunotherapy strategies that test patients with NY-ESO-1-expressing sarcomas, mostly in active recruitment phases in 2014. Some vaccine studies use a low NY-ESO-1 positivity cutoff value of 45%, hoping that the vaccine can still elicit an immune response in these patients.
Primary central chondrosarcoma is a bone sarcoma, accounting for approximately 20% of malignant bone tumors. 28 As it is highly resistant to existing chemotherapeutic agents, the search for new targeted therapies is ongoing. Our study revealed positivity for NY-ESO-1 in 28.2% (40/142) of conventional chondrosarcoma and 10.0% (3/30) of dedifferentiated chondrosarcoma specimens, whereas clear cell and mesenchymal chondrosarcomas were all negative. Lai et al 7, 32 reported that one out of two tested chondrosarcomas showed immunoreactivity for NY-ESO-1, and a relatively low NY-ESO-1 mRNA expression level was found in 4 out of 11 cases in another study. Although the number of positive cases is relatively low, immunotherapy may be of significance in a subset of these patients, who are not included in the eligibility criteria for some of the existing clinical trials.
Apart from the 6 of 17 tested myxofibrosarcomas and 1 of 3 pleomorphic rhabdomyosarcomas, the other tested types of mesenchymal tumors were almost uniformly negative for NY-ESO-1 expression. Although our study included over 1132 cases, the numbers of some rare sarcomas are too limited to draw final conclusions on NY-ESO-1 expression in these subtypes. In summary, we confirm that NY-ESO-1 can be reliably detected by immunohistochemistry. Using previously described scoring criteria, but based on much larger numbers of samples than have been assessed previously, we confirm very high frequencies of NY-ESO-1 expression in myxoid liposarcomas, high frequencies in synovial sarcomas, and we find similar levels of expression in 28.2% of conventional chondrosarcomas. Clinical trials of NY-ESO-1 targeted therapies should be open to patients with positive histologies, and NY-ESO-1 expression by immunohistochemistry should be considered as a potential entry criteria or integrated stratification as a potential predictive marker for such therapeutic strategies. NY-ESO-1 positivity in the remaining subtypes of mesenchymal tumors was rare. Benign bone and soft tissue lesions showed no positivity for NY-ESO-1, supporting the limited level of expression of this biomarker in normal tissues and the possibility that targeted therapies will have limited side effects.
